Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drospirenone - Exeltis USA

Drug Profile

Drospirenone - Exeltis USA

Alternative Names: Drospirenone-only pill - Exceltis USA; DRSP-only oral contraceptive - Leon Farma; LF-111; LPRI-CF113; Slinda; Slynd

Latest Information Update: 29 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exeltis USA
  • Developer Chemo Research, S.L.; Duchesnay Inc; Exeltis USA; Leon Farma
  • Class Androstenes; Antiandrogens; Oral contraceptives; Progesterone congeners
  • Mechanism of Action Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy
  • Phase III Endometriosis

Most Recent Events

  • 04 Aug 2022 Phase-III clinical trials in Pregnancy (In adolescents, In adults, Prevention) in USA (PO) (NCT05461573)
  • 18 Jul 2022 Exeltis USA plans a Phase III trial for Pregnancy (In adolescents, In adults, Prevention)(PO) (NCT05461573) (CF113-303)
  • 17 May 2022 Launched for Pregnancy (Prevention) in Canada (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top